

# 東邦大学学術リポジトリ

Toho University Academic Repository

タイトル	Late Chemotherapy Induced Nausea and Vomiting after Cisplatin Treatment for Patients with Esophageal or Gastric Cancer
別タイトル	食道癌または胃癌患者に対するシスプラチン投与後6日目以降まで残存する超遅発性嘔気・嘔吐に関する調査
作成者（著者）	西澤, 広介 / 島田, 英昭 / 伊藤, 正朗 / 大嶋, 陽幸 / 谷島, 聡 / 住野, 泰清 / 金子, 弘真 / 大林, 雅彦
公開者	東邦大学医学会
発行日	2014.09
ISSN	00408670
掲載情報	東邦医学会雑誌. 61(5). p.218-223.
資料種別	学術雑誌論文
内容記述	原著
著者版フラグ	publisher
JaLCDOI	info:doi/10.14994/tohoigaku.61.218
メタデータのURL	<a href="https://mylibrary.toho-u.ac.jp/webopac/TD35615398">https://mylibrary.toho-u.ac.jp/webopac/TD35615398</a>

# Late Chemotherapy-Induced Nausea and Vomiting after Cisplatin Treatment for Patients with Esophageal or Gastric Cancer

Kosuke Nishizawa<sup>1)\*</sup> Hideaki Shimada<sup>2)</sup> Masaaki Ito<sup>2)</sup>  
Yoko Oshima<sup>2)</sup> Satoshi Yajima<sup>2)</sup> Yasukiyo Sumino<sup>3)</sup>  
Hironori Kaneko<sup>2)</sup> and Masahiko Obayashi<sup>4)</sup>

<sup>1)</sup>Department of Pharmacy, Toho University Omori Medical Center

<sup>2)</sup>Division of General and Gastroenterological Surgery (Omori), Department of Surgery,  
School of Medicine, Faculty of Medicine, Toho University

<sup>3)</sup>Division of Gastroenterology and Hepatology (Omori), Department of Internal Medicine,  
School of Medicine, Faculty of Medicine, Toho University

<sup>4)</sup>Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Toho University

---

## ABSTRACT

**Background:** Chemotherapy-induced nausea and vomiting (CINV) usually resolves within 5 days of chemotherapy initiation. However, some patients have CINV at 6 days or later after chemotherapy initiation (late CINV). We evaluated the incidence of late CINV and the effectiveness of aprepitant plus palonosetron in preventing late CINV.

**Methods:** We retrospectively reviewed the records of 102 patients with esophageal or gastric cancer to determine CINV incidence on days 1 through 21 after initiation of cisplatin treatment. Sixty-six patients received a first-generation 5-hydroxytryptamine (serotonin) type 3 receptor antagonist, and 36 received aprepitant plus palonosetron. In addition, we compared the effectiveness of antiemetic regimens before and after administering aprepitant and palonosetron. CINV was defined as presence of grade 1 or higher vomiting or grade 2 or higher nausea.

**Results:** In the aprepitant plus palonosetron group, the highest incidence of CINV (42%) was seen at 7 days after initiation of cisplatin treatment. CINV incidence started to gradually decrease at 8 days after cisplatin initiation. There was no significant intergroup difference in the incidence of late CINV.

**Conclusions:** Late CINV may develop in patients receiving cisplatin for treatment of esophageal or gastric cancer. Our findings suggest that the widely used prophylaxis for delayed CINV resulting from highly emetogenic chemotherapy is not satisfactorily effective against late CINV.

**J Med Soc Toho 61 (5): 218–223, 2014**

---

**KEYWORDS:** chemotherapy-induced nausea and vomiting (CINV), antiemetics, aprepitant, palonosetron

---

1, 2, 3) 6-11-1 Omorinishi, Ota, Tokyo 143-8541

4) 2-2-1 Miyama, Funabashi, Chiba 274-8510

\*Corresponding Author: tel: 03 (3762) 4151

e-mail: k-nishizawa@med.toho-u.ac.jp

Received May 2, 2014; Accepted July 17, 2014

Journal of the Medical Society of Toho University

61 (5), Sept. 1, 2014. ISSN 0040-8670, CODEN: TOIZAG

Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects for patients with cancer.<sup>1,2)</sup> Patients who develop CINV are occasionally forced to discontinue or postpone chemotherapy, which can worsen clinical outcomes.

According to the cisplatin treatment model, acute CINV is defined as emesis during the first 24 hours of treatment, and delayed CINV is defined as emesis after 24 hours of treatment. Cisplatin-containing chemotherapy is the most frequent treatment option for upper gastrointestinal cancer. The Japan Clinical Oncology Group (JCOG) 9907 study recommends preoperative chemotherapy (*i.e.*, cisplatin and 5-fluorouracil) followed by surgical resection as the standard of care for patients with esophageal carcinoma.<sup>3)</sup> On the basis of the results of S-1 plus cisplatin versus S-1 alone for the first-line treatment of advanced gastric cancer trial (the SPIRITS trial), combination chemotherapy with cisplatin plus S-1 (a mixture of tegafur, gimeracil, and oteracil potassium) is considered the standard chemotherapy regimen for patients with advanced gastric cancer.<sup>4)</sup> However, cisplatin is highly emetogenic, with a greater than 90% risk of CINV.<sup>5)</sup> To prevent CINV in patients receiving highly emetogenic chemotherapy, the antiemetic guidelines<sup>6,7)</sup> suggest the use of 3 antiemetic drugs: a neurokinin-1 (NK1) receptor antagonist, a 5-hydroxytryptamine (serotonin) type 3 receptor antagonist (5-HT<sub>3</sub>RA), and dexamethasone. In particular, the NK1 receptor antagonist aprepitant was found to significantly decrease the incidence of acute and delayed CINV.<sup>8)</sup> Although first-generation 5-HT<sub>3</sub>RAs such as granisetron, ramosetron, ondansetron, and azasetron have shown considerable efficacy in preventing acute CINV, palonosetron—a second-generation 5-HT<sub>3</sub>RA—was more effective than first-generation 5-HT<sub>3</sub>RAs in preventing acute and delayed emesis.<sup>9-11)</sup>

Although CINV usually resolves within 5 days after chemotherapy initiation,<sup>7)</sup> some patients have CINV at 6 days or later. In this study, we defined substantially delayed CINV as “late” CINV. Although several studies found that aprepitant and/or palonosetron were effective in treating CINV within 5 days after initiation of cisplatin treatment,<sup>11-13)</sup> no study evaluated the effectiveness of these agents in preventing late CINV. Therefore, we evaluated the incidence of late CINV and the effectiveness of aprepitant plus palonosetron in preventing late CINV.

## Methods

### Patients and treatment

We retrospectively reviewed the records of patients treated at Toho University Omori Medical Center for esophageal or gastric cancer during the period from July 2010 through June 2012. The following inclusion criteria were applied: (1) age 20 years or older, (2) treatment with cisplatin (50 mg/m<sup>2</sup> or greater), (3) no prior chemotherapy, (4) no emesis within 24 hours before cisplatin administration, (5) absence of a brain metastasis, and (6) absence of gastrointestinal disturbances. Thirty-six consecutive patients treated with aprepitant, palonosetron, and dexamethasone were analyzed (aprepitant plus palonosetron group). Sixty-six consecutive patients treated with first-generation 5-HT<sub>3</sub>RAs and dexamethasone from January 2009 through June 2010 were included as a historical control (first-generation 5-HT<sub>3</sub>RA group).

All data on CINV episodes were extracted from patient medical records. This study was approved by the Ethical Review Board of Toho University Omori Medical Center (No. 23-2).

### Chemotherapy

Patients with esophageal cancer were administered cisplatin 80 mg/m<sup>2</sup> via intravenous (IV) drip infusion for 2 hours on day 1 and 5-fluorouracil 800 mg/m<sup>2</sup> using continuous infusion on days 1 through 5. Patients with gastric cancer were administered oral S-1 twice daily for 3 weeks. S-1 doses were calculated according to the patient's body surface area, as follows: less than 1.25 m<sup>2</sup>, 40 mg; 1.25 through 1.5 m<sup>2</sup>, 50 mg; and greater than 1.5 m<sup>2</sup>, 60 mg. Cisplatin 60 mg/m<sup>2</sup> was administered via IV drip infusion for 2 hours on day 8.

### Antiemetic treatment

In the first-generation 5-HT<sub>3</sub>RA group, first-generation 5-HT<sub>3</sub>RA (granisetron, 3 mg; ramosetron, 0.3 mg; and azasetron, 10 mg) and dexamethasone infusion (IV 9.9 mg) were administered in a single IV infusion approximately 30 minutes before cisplatin administration. In the aprepitant plus palonosetron group, eligible patients were given oral aprepitant (125 mg), palonosetron infusion (IV 0.75 mg), and dexamethasone infusion (IV 9.9 mg) before the cisplatin infusion. Oral aprepitant (80 mg) was administered on 2 subsequent days and oral dexamethasone (8 mg) was given on 3 subsequent days. All patients were given a prescription for a rescue antiemetic if nausea or vomiting developed during the observation period.

Table 1 Patient characteristics

	Antiemetic therapy regimen		p value
	First-generation 5-HT <sub>3</sub> RA	Aprepitant plus palonosetron	
Number of patients	66	36	
Duration of data collection (months)	18	24	
Age (years), median (range)	62 (31–84)	67 (46–77)	p = 0.06*
Sex (Male/Female)	58/8	29/7	p = 0.32†
Cisplatin dose (mg/m <sup>2</sup> ), median (range)	60 (56–80)	70 (60–80)	p = 0.01*
Primary cancer diagnosis			
Esophagus/Stomach	32/34	28/8	p < 0.01†

\*Mann-Whitney *U* test, †Chi-square test  
5-HT<sub>3</sub>RA: serotonin type 3 receptor antagonist

### Observation period and study outcome measures

The observation period after cisplatin infusion was divided into 3 phases: acute (0–24 hours), delayed (days 2–5), and late (days 6–21). The primary endpoint was CINV incidence during the late phase. CINV was defined as grade 1 or higher vomiting or grade 2 or higher nausea (according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4).

### Statistical analysis

The chi-square test and Mann-Whitney *U* test were used to assess relationships among patient variables. In addition, either Fisher's exact probability test or the chi-square test was used to compare CINV incidence between the first-generation 5-HT<sub>3</sub>RA group and aprepitant plus palonosetron group. A *p* value of less than 0.05 were considered to indicate statistical significance.

## Results

### Characteristics of patients and chemotherapy regimens

The characteristics of the patients are summarized in Table 1. The esophageal cancer/gastric cancer ratio was higher in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group. In addition, cisplatin doses were significantly higher in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group.

### Incidence of CINV

Late CINV was observed in both groups (Fig. 1). At 6 through 10 days after cisplatin infusion, late CINV was observed in 25% to 42% patients in the aprepitant plus palonosetron group. In this group, the highest incidence of CINV (42%) was seen at 7 days after cisplatin treatment. Although CINV incidence gradually decreased after that,

approximately 10% of patients had late CINV at 14 days after cisplatin treatment. In the first-generation 5-HT<sub>3</sub>RA group, the highest CINV incidence (63%) was observed at 4 days after cisplatin treatment. Although CINV incidence gradually decreased after that, 39% patients had late CINV at 6 days after cisplatin treatment.

In the acute phase (day 1), there was no significant intergroup difference in CINV incidence. In the delayed phase (days 2 through 5), CINV incidence was significantly lower in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group, except on day 5. In the late phase (days 6 through 21), there was no significant intergroup difference in CINV incidence.

## Discussion

Our data show that some patients who received cisplatin treatment for esophageal or gastric cancer had late CINV. This suggests that the widely used prophylaxis for delayed CINV resulting from highly emetogenic chemotherapy is not sufficiently effective against late CINV.

Although cisplatin doses were higher in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group in the present study, aprepitant plus palonosetron therapy was effective in suppressing acute and delayed CINV. Nevertheless, the incidence of late CINV was similar in these groups. In fact, the incidence of late CINV was higher in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group, although the difference was not significant. The fact that the aprepitant plus palonosetron therapy was so effective during the delayed phase might have made patients in that group more likely to report late CINV, as compared with patients in the first-generation 5-HT<sub>3</sub>RA group. In 2003 Hesketh et al. reported that a 3-day aprepitant regimen protected patients against




Fig. 1 CINV incidence. CINV was defined as grade 1 or higher vomiting or grade 2 or higher nausea. The first day after cisplatin infusion was set as day 1. Each patient was evaluated on day 1 (acute phase), days 2 through 5 (delayed phase), and days 6 through 21 (late phase). Group differences were analyzed using Fisher's exact probability test or the chi-square test.

CINV: chemotherapy-induced nausea and vomiting, 5-HT<sub>3</sub>RA: serotonin type 3 receptor antagonist

CINV during a 5-day observation period.<sup>12)</sup> Herrington et al. reported a trend toward better effectiveness in preventing nausea on days 4 and 5 after cisplatin treatment with 3-day versus 1-day aprepitant administration.<sup>8)</sup> This observation suggests that a regimen of 4 or more days of aprepitant administration is better than a 3-day regimen in preventing late CINV in patients receiving cisplatin.

A recent study showed that prochlorperazine was as effective as aprepitant in preventing delayed CINV.<sup>14)</sup> Another study reported that a combination of olanzapine, dexamethasone, and palonosetron was effective in controlling acute and delayed CINV in patients receiving highly emetogenic chemotherapy.<sup>15)</sup> In addition, a recent phase III trial found that oral olanzapine was significantly better than oral metoclopramide in controlling breakthrough CINV.<sup>16)</sup>

There are several limitations to our study. Retrospective studies are subject to two types of bias. First, physicians had different standards for CINV assessment. Second, the characteristics of the patients and chemotherapy regimens significantly differed between the two patient groups. For instance, because of the difference in esopha-

geal cancer/gastric cancer ratio, cisplatin doses were significantly higher in the aprepitant plus palonosetron group than in the first-generation 5-HT<sub>3</sub>RA group.

## Conclusion

Although delayed CINV was significantly suppressed by aprepitant plus palonosetron therapy, 42% patients still experienced late CINV. Therefore, longer administration of antiemetic treatment, e.g., aprepitant administration for 4 days or longer, may be needed to control late CINV. Prospective studies are required in order to evaluate the effectiveness of antiemetic treatments against late CINV.

**Conflict of interest:** The authors have no conflicts of interest to declare.

## References

- 1) de Boer-Dennert M, de Wit R, Schmitz PIM, et al: Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. *Br J Cancer* **76**: 1055-1061, 1997
- 2) Sun CC, Bodurka DC, Weaver CB, et al: Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. *Support Care Cancer* **13**:

- 219–227, 2005
- 3) Ando N, Kato H, Igaki H, et al.: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). *Ann Surg Oncol* **19**: 68–74, 2012
  - 4) Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. *Lancet Oncol* **9**: 215–221, 2008
  - 5) Roila F, Hesketh PJ, Herrstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. *Ann Oncol* **17**: 20–28, 2006
  - 6) Basch E, Prestrud AA, Hesketh PJ, et al.: Antiemetics: American Society Clinical Oncology clinical practice guideline update. *J Clin Oncol* **29**: 4189–4198, 2011
  - 7) Nihon Gan Chiryō Gakkai (Ed): *Seitoyaku Tekisei Shiyō Gaidorain 2010*. Kanehara, Tokyo, 2010 (J)
  - 8) Herrington JD, Jaskiewicz AD, Song J: Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. *Cancer* **112**: 2080–2087, 2008
  - 9) Eisenberg P, Figueroa-Vadillo J, Zamora R, et al.: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT<sub>3</sub> receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. *Cancer* **98**: 2473–2482, 2003
  - 10) Gralla R, Lichinitser M, Van der Vegt S, et al.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. *Ann Oncol* **14**: 1570–1577, 2003
  - 11) Saito M, Aogi K, Sekine I, et al.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomized, comparative phase III trial. *Lancet Oncol* **10**: 115–124, 2009
  - 12) Hesketh PJ, Grunberg SM, Gralla RJ, et al.: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—The Aprepitant Protocol 052 Study Group. *J Clin Oncol* **21**: 4112–4119, 2003
  - 13) Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al.: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. *Cancer* **97**: 3090–3098, 2003
  - 14) Roscoe JA, Heckler CE, Morrow GR, et al.: Prevention of delayed nausea: A University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. *J Clin Oncol* **30**: 3389–3395, 2012
  - 15) Navari RM, Gray SE, Kerr AC: Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. *J Support Oncol* **9**: 188–195, 2011
  - 16) Navari RM, Nagy CK, Gray SE: The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. *Support Care Cancer* **21**: 1655–1663, 2013  
(J): in Japanese

# 食道癌または胃癌患者に対するシスプラチン投与後 6日目以降まで残存する超遅発性嘔気・嘔吐に関する調査

西澤 広介<sup>1)</sup> 島田 英昭<sup>2)</sup> 伊藤 正朗<sup>2)</sup>  
大嶋 陽幸<sup>2)</sup> 谷島 聡<sup>2)</sup> 住野 泰清<sup>3)</sup>  
金子 弘真<sup>2)</sup> 大林 雅彦<sup>4)</sup>

<sup>1)</sup>東邦大学医療センター大森病院薬剤部

<sup>2)</sup>東邦大学医学部外科学講座一般・消化器外科学分野 (大森)

<sup>3)</sup>東邦大学医学部内科学講座消化器内科学分野 (大森)

<sup>4)</sup>東邦大学薬学部臨床薬剤学研究室

---

## 要約

**背景と目的:** 抗がん剤により引き起こされる嘔気・嘔吐 (chemotherapy-induced nausea and vomiting : CINV) は, 投与後5日以内に消失すると考えられている. しかし, 6日目以降も嘔気を訴える「超遅発性 CINV」の患者も散見される. 超遅発性 CINV の発現頻度と, アプレピタント+パロノセトロン<sup>1)</sup>の制吐効果を調査した.

**対象および方法:** 食道癌または胃癌の患者 102 名を対象に, シスプラチン投与後 21 日間の CINV 発現頻度を後ろ向きに調査した. アプレピタント+パロノセトロン<sup>1)</sup>の採用前後での制吐療法の効果も比較した.

**結果:** アプレピタント+パロノセトロン<sup>1)</sup>群では, シスプラチン投与後 7 日目に CINV 発現頻度が最高値 (42%) となった. 超遅発性期では, 2 群間の制吐効果に有意差はなかった.

**結論:** シスプラチン投与を受ける食道癌または胃癌患者において, 超遅発性 CINV が存在することが示された. 広く使われている制吐療法が, 超遅発性 CINV に対しては効果が十分ではないことが示唆された.

東邦医学会誌 61 (5): 218-223, 2014

---

索引用語: 悪心, 嘔吐, 制吐薬, アプレピタント, パロノセトロン